Articles: 30.06 June 2019

The environmental impact of prescribing

In this editorial, Rupert Payne, Consultant Editor on Prescriber, discusses the recent media interest around the environmental impact of medical prescribing. 

More details...

New approaches to defusing the dementia time bomb

As the prevalence of dementia in the UK continues to rise, there is a desperate clinical need for new therapies. Many drug candidates that have shown promise in early clinical trials have failed in late-phase studies, but novel approaches, such as combination therapy and earlier diagnosis and intervention, may offer more hope for the future

More details...

Diagnosis and management of gonorrhoea: a guide for GPs

With gonorrhoea infection rates at their highest since the 1970s and antibiotic resistance increasing, prompt identification and referral to a GUM clinic for testing and treatment is important. This article discusses the diagnosis of gonorrhoea, current recommended treatment options and the GP’s place in management

More details...

Primary care hypertension clinics: tips for pharmacist prescribers

In the first of our two-part series on helping pharmacist independent prescribers set up a hypertension clinic in primary care, the author discusses the importance of drawing up a treatment plan and the practicalities of running the clinic

More details...

A practical guide to chronic heart failure management

Despite significant recent advances, heart failure remains a challenging condition to both diagnose and treat. This article discusses the recommended investigations to aid diagnosis and the role of pharmacotherapy in the management of chronic heart failure.

More details...

Antimicrobial prescribing for urinary tract infections

NICE has recently published a comprehensive set of guidelines on antimicrobial prescribing for urinary tract infections, covering lower urinary tract infection, acute prostatitis, acute pyelonephritis, recurrent infection and catheter-associated infection. This article provides a summary of the recommendations

More details...

Tildrakizumab for the treatment of plaque psoriasis in adults

Tildrakizumab (Ilumetri) is a new biological therapy targeting interleukin (IL)-23 for the treatment of plaque psoriasis in adults. This article discusses its place in therapy and clinical trial efficacy

More details...

Web design and marketing agency Leamington Spa